Do not throw the baby out with the bathwater: SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding

Ann Oncol. 2017 Sep 1;28(9):2321-2322. doi: 10.1093/annonc/mdx251.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / administration & dosage
  • Cell Differentiation / physiology
  • Dose-Response Relationship, Drug
  • Hemorrhage / chemically induced
  • Hemorrhage / therapy
  • Humans
  • Male
  • Phenylurea Compounds / administration & dosage*
  • Phenylurea Compounds / adverse effects
  • Precision Medicine
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects
  • Quinolines / administration & dosage*
  • Quinolines / adverse effects
  • Thyroid Neoplasms / drug therapy*
  • Thyroid Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Quinolines
  • lenvatinib